Human clinical trials planned for new anti-cancer compound
23 April 2015
After a decade of discovery and research, two University of Auckland medical oncology researchers along with their dedicated teams have developed a new anti-cancer compound that will advance to human phase two clinical trials. The co-inventors of the compound TH-4000, Dr Ad...
Promising New Zealand compound selected as drug candidate for tuberculosis
17 September 2012
A New Zealand-designed compound that shows promise against treatment-resistance tuberculosis (TB) has been selected as a drug candidate by international non-profit drug developer the Global Alliance for TB Drug Development (TB Alliance).
Local cancer drug approved for first clinical trial in United States and New Zealand
30 August 2012
The US Food and Drug Administration (FDA) has granted approval for PR610, an anticancer “stealth” drug invented in New Zealand, to move forward to human clinical trials through its approval of an Investigational New Drug (IND) Application for the drug.
Second New Zealand anticancer “stealth” drug targeted for clinical development
4 August 2011
A second anticancer “stealth” drug designed by New Zealand scientists has been targeted for clinical development under a collaborative agreement between Proacta Incorporated (San Diego) and Yakult Honsha Co., Ltd. (Tokyo).